Focused on slowing CKD progression through the treatment of metabolic acidosis
Tricida is developing a drug candidate that may have the potential to address a significant unmet medical need in the treatment of patients with metabolic acidosis and CKD.
About Metabolic Acidosis
Metabolic Acidosis is a serious condition commonly caused by CKD
About Veverimer
Our investigational drug, veverimer, is a novel, non-absorbed polymer that binds and removes acid from the GI tract.
About Tricida
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate
For Investors
Visit the investors section to learn more about Tricida.
Tricida recently completed the VALOR-CKD renal outcomes clinical trial to determine if veverimer slows CKD progression in patients with metabolic acidosis and CKD.